Skip To Main Content

Transplantační medicína

Nejnovější trendy

Prozkoumejte nejčtenější články a videa na Campus Sanofi

Seřadit

Effective Treatment Simplification

Prof. Robert Ritzel, Division of Endocrinology, Munich and University of Heidelberg, Germany, presents effective treatment simplification for people with T2D using fixed ration combination of iGlarLixi.

Suliqua® - Lepsze wyniki w leczeniu cukrzycy typu 2

Concientización sobre tos ferina

La tos ferina es una infección altamente contagiosa de los pulmones y las vías respiratorias. Puede ser grave, especialmente para bebés, niños pequeños y niños en edad escolar.1,2  La vacunación es clave para  prevenir complicaciones graves.

Hexacima: Estrategia de Vacunación

Esta infografía resume la revisión sobre Hexacima®, vacuna DTaP-IPV-HB-Hib, diez años después de su autorización inicial. Experto Rev Vacunas 2023.​

Hva er Toujeo?

Toujeo er en andre generasjons, langtidsvirkende insulinanalog som inneholder insulin glargin 300 enheter/ml. Toujeo® senker blodsukkernivået jevnt over en lang periode. Det trenger derfor å adminisreres kun en gang daglig.

DELIVER-G: Real-world analysis in insulin-naïve adults with T2DM on GLP-1 RA ± OAD(s), intensifying their therapy by starting basal insulin and discontinuing GLP-1 RA, or adding basal insulin to ongoing GLP-1 RA, or initiating a FRC product and discontinuing current GLP-1 RA†1

DELIVER-G: Real-world analysis in insulin-naïve adults with T2DM on GLP-1 RA ± OAD(s), intensifying their therapy by starting basal insulin and discontinuing GLP-1 RA, or adding basal insulin to ongoing GLP-1 RA, or initiating a FRC product and discontinuing current GLP-1 RA†1

EVEREST study: First ever direct Head-to-Head Comparison of Biologics in Patients with Severe CRSwNP and Coexisting Asthma

First ever direct Head-to-Head Comparison of Biologics in Patients with Severe CRSwNP and Coexisting Asthma.

EVEREST study: First ever direct Head-to-Head Comparison of Dupilumab vs Omalizumab in Patients with Severe CRSwNP and Coexisting Asthma

First ever direct Head-to-Head Comparison of Dupilumab vs Omalizumab in Patients with Severe CRSwNP and Coexisting Asthma.

EVEREST study: First ever direct Head-to-Head Comparison of Dupilumab vs Omalizumab in Patients with Severe CRSwNP and Coexisting Asthma

First ever direct Head-to-Head Comparison of Dupilumab vs Omalizumab in Patients with Severe CRSwNP and Coexisting Asthma.

EVEREST study: First ever direct Head-to-Head Comparison of Dupilumab vs Omalizumab in Patients with Severe CRSwNP and Coexisting Asthma

First ever direct Head-to-Head Comparison of Dupilumab vs Omalizumab in Patients with Severe CRSwNP and Coexisting Asthma.

EVEREST study: First ever direct Head-to-Head Comparison of Dupilumab vs Omalizumab in Patients with Severe CRSwNP and Coexisting Asthma

First ever direct Head-to-Head Comparison of Dupilumab vs Omalizumab in Patients with Severe CRSwNP and Coexisting Asthma.

Weryfikacja statusu szczepienia przeciwko tężcowi u dzieci przyjętych z powodu pogryzień przez zwierzęta w pediatrycznym oddziale ratunkowym: wyniki badań i implikacje kliniczne

Tężec pozostaje potencjalnie śmiertelną infekcją, szczególnie u pacjentów z ranami wysokiego ryzyka, takimi jak pogryzienia przez zwierzęta. Mimo że zachorowania są rzadkie w krajach o wysokim poziomie dochodów, luki w szczepieniach lub brak dokumentacji mogą narażać dzieci na możliwą do uniknięcia chorobowość.